Deals
Syneron Bio Closes $150M Series B for Peptides
Syneron Bio raised a $150M Series B for peptide development. GLP-1s proved the format can print billions. The program list is still a mystery.
Deals — Page 8
M&A, fundraising, IPOs, and bankruptcies in regulated industries.
Deals
Neurocrine Buys Soleno for $2.9B, Betting 15x Revenue on Rare Hunger Drug
Neurocrine is paying $2.9B at ~15x trailing revenue for Soleno's Vykat XR, the only approved drug for Prader-Willi hunger, in its biggest-ever deal.
Deals
Anthropic Drops $400M on Six-Person Drug Discovery Startup
Anthropic acquires six-person AI biotech Coefficient Bio for $400M in stock — $66M per employee for a company founded in 2025 with no public product.
Deals
Takeda Walks Away From $150M Denali Dementia Bet After 8 Years
Takeda returns frontotemporal dementia drug DNL593 to Denali after 8 years and $150M, citing strategy—not safety—days after Denali's FDA approval win.
Deals
Anthropic Pays $400M for a 10-Person Ghost Company
Anthropic is paying ~$400M for Coefficient Bio, a sub-10-person stealth startup. The price signals how expensive life sciences AI talent has become.
Deals
Stipple Bio Raises $100M to Pinpoint Cancer Drug Targets
Stipple Bio launches with $100M to identify precise targets on cancer proteins, betting the ADC industry's real problem is aim, not ammo.
Deals
Neurocrine Pays $2.9B for Soleno's Prader-Willi Drug
Neurocrine pays $53/share in cash for Soleno Therapeutics, acquiring Vykat XR, a profitable approved treatment for Prader-Willi syndrome.
Deals
Gilead Cuts 51 Foster City Jobs One Year After Same Layoff
Gilead cuts 51 Foster City jobs effective May 29, one year after the same HQ shed 149. The backdrop: ~$10B in acquisitions closed since February.
Deals
Syneron Bio Pulls $150M Series B Four Months After $100M Round
Syneron Bio raises $150M Series B, bringing total funding to $250M in four months, backed by AstraZeneca and Abu Dhabi sovereign wealth.
Deals
OpenEvidence Buys Tandem to Automate Prior Authorization
OpenEvidence acquires Tandem to add AI-driven prior authorization to its doctor-facing platform, threatening standalone PA automation vendors.
Deals
Lilly Pays $115M Upfront in Insilico AI Deal Worth Up to $2.75B
Eli Lilly paid $115M upfront for an AI collaboration with Insilico Medicine worth up to $2.75B, with milestone math that heavily favors Lilly.
Deals
Blackstone Raises New Fund as Two Pharma Giants Close March Megadeals
Two pharma giants closed megadeals in March while Blackstone raised a new fund — more dry powder chasing the same targets means multiples only go one way.
Deals
Biogen Drops $5.6B for Apellis at 140% Premium, Shares Fall
Biogen acquires Apellis for $5.6B at a near 140% premium, adding Syfovre and Empaveli to offset a fading MS franchise ahead of pharma's patent cliff.
You've reached the end of the archive.
Want the next stories in your inbox? Subscribe to the newsletter